Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Madrigal Pharma Appoints President of R&D | Contract Pharma

What are you searching for?

Sign in
Promotions & Moves

Madrigal Pharma Appoints President of R&D

Rebecca Taub to head Phase III development of resmetirom in both NASH and earlier stage dyslipidemias

By: Cassandra Gervolino

Madrigal Pharmaceuticals, Inc. has promoted Rebecca Taub, M.D., to the newly created position of President of Research & Development. 
 
Dr. Taub has served as Chief Medical Officer and Executive Vice President of Research & Development, of Madrigal  since 2016. She is also a member of the Company’s Board of Directors.
 
Paul Friedman, M.D., Chairman and CEO of Madrigal, stated, “As we continue to advance resmetirom forward in Phase 3 clinical development in both NASH and earlier stage NASH/NAFLD patients with dyslipidemias, and as we seek to add to the professional resources of the Company, Becky’s leadership as President of R&D promises to be of great value to all of our key stakeholders.”
 
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters